scholarly journals 21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients

The Breast ◽  
2009 ◽  
Vol 18 (3) ◽  
pp. 171-174 ◽  
Author(s):  
Sadako Akashi-Tanaka ◽  
Chikako Shimizu ◽  
Masashi Ando ◽  
Tatsuhiro Shibata ◽  
Noriyuki Katsumata ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Breast Cancer Patients ◽  
Neoadjuvant Endocrine Therapy ◽  
Core Needle

Abstract 4267: Gene expression profile of fibroblasts from different topographical origins in breast cancer patients

2012 ◽  
Author(s):  
Paulo Roberto Del Valle ◽  
Maria Lucia Hirata Katayama ◽  
Patricia Bortman Rozenchan ◽  
Cintia Milani ◽  
Eduardo Carneiro Lyra ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Cancer Patients ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Breast Cancer Patients

Integrated gene expression profile predicts prognosis of breast cancer patients

2008 ◽  
Vol 113 (2) ◽  
pp. 231-237 ◽  
Author(s):  
Lian-Fang Li ◽  
Xiao-Jing Xu ◽  
Ying Zhao ◽  
Zhe-Bing Liu ◽  
Zhen-Zhou Shen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Cancer Patients ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Breast Cancer Patients

scholarly journals Gene expression profile of stromal cells from potential metastatic sites in breast cancer patients

2013 ◽  
Vol 7 (S2) ◽  
Author(s):  
Paulo R Del Valle ◽  
Maria LH Katayama ◽  
Dirce M Carraro ◽  
Renato Puga ◽  
Eduardo C Lyra ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Cancer Patients ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Stromal Cells ◽  
Breast Cancer Patients ◽  
Metastatic Sites

scholarly journals P205 The 70-gene expression profile, Mammaprint, for breast cancer patients in mainly European hospitals

The Breast ◽  
2011 ◽  
Vol 20 ◽  
pp. S45 ◽  
Author(s):  
F. Zanconati ◽  
P. Cusumano ◽  
C. Tinterri ◽  
A. Di Napoli ◽  
M. Lutke Holzik ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Cancer Patients ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Breast Cancer Patients

Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients – A phase II trial

2014 ◽  
Vol 50 (13) ◽  
pp. 2190-2200 ◽  
Author(s):  
Duveken B.Y. Fontein ◽  
Ayoub Charehbili ◽  
Johan W.R. Nortier ◽  
Elma Meershoek-Klein Kranenbarg ◽  
Judith R. Kroep ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Phase Ii ◽  
Hormone Receptor ◽  
Phase Ii Trial ◽  
Breast Cancer Patients ◽  
Neoadjuvant Endocrine Therapy ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer

A phase III, open label, prospective, randomized, multicenter, neoadjuvant study of chemotherapy versus endocrine therapy in premenopausal patient with hormone responsive, HER2 negative, breast cancer (KBCSG 012).

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 517-517
Author(s):  
hee Jeong Kim ◽  
Woo Chul Noh ◽  
Eun Sook Lee ◽  
Leesu Kim ◽  
Yongsik Jung ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Endocrine Treatment ◽  
Breast Cancer Patients ◽  
Neoadjuvant Endocrine Therapy ◽  
Premenopausal Breast Cancer ◽  
Ki 67 ◽  
Initial Biopsy

517 Background: Neoadjuvant endocrine therapy has shown efficacy in hormone-responsive postmenopausal breast cancer patients. We aimed to assess the efficacy and safety of cytotoxic chemotherapy versus endocrine therapy for hormone-responsive lymph node-positive premenopausal breast cancer patients in a neoadjuvant setting. (NCT01622361). Methods: In this phase 3, randomized, double blind, parallel group, multicenter study, we enrolled premenopausal women with estrogen receptor (ER)-positive, HER2-negative, and lymph node-positive premenopausal breast cancer patients. Patients were randomized to either 24 weeks of neoadjuvant chemotherapy with adriamycin plus cyclophosphamide (AC) followed by taxane (T) or neoadjuvant endocrine therapy with zoladex and tamoxifen. Results: 187 patients were randomly assigned to chemotherapy (n=95) or endocrine therapy (n=92), and 174 patients completed the 24 week neoadjuvant treatment period (n=87, both). More patients in the chemotherapy group had a complete or partial response than did those in endocrine therapy arm on both caliper (chemotherapy 83.9% vs endocrine therapy 71.3%, OR 0.476 95% CI 0.228 to 0.994) and MRI (chemotherapy 83.7% vs endocrine therapy 52.9%, OR 0.219, 95% CI 0.107 to 0.447). Three patient on chemotherapy group (3.4%) and 1 patients (1.15%) on endocrine treatment group showed complete pathologic response. In the patients who had breast cancer with low Ki 67 expression (<20%) on initial biopsy, clinical response on caliper were shown similar on both treatment group (HR 0.958, 95%CI 0.296 to 3.101). Five patients who had no tumor on the breast or lymph node after 24 week neoadjuvant endocrine therapy had higher ER score (all allred score >6), all low grade (1or 2) low Ki 67(≤20%) expression (4/5 patients) on initial biopsy specimen. Conclusions: In premenopausal breast cancer patients, 24 weeks neoadjuvant chemotherapy showed better clinical response than endocrine therapy. Low Ki 67 expression could be a parameter of the endocrine treatment. Clinical trial information: NCT01622361.

Sign in / Sign up

Export Citation Format

Share Document